Transplantační medicína

This article highlights Gaucher Disease, a rare genetic disorder caused by GBA1 mutations, resulting in enzyme deficiency and glucosylceramide accumulation. It causes organ damage, especially in the spleen and liver. Diagnosis delays are frequent; treatment involves enzyme replacement therapy. Early diagnosis and multidisciplinary management are crucial for effective patient care. This article discusses Gaucher Disease, its diagnostic challenges and approach and touches on multidisciplinary management. MAT-ZA-2500623

The usual starting dose for PRALUENT is 75 mg administered subcutaneously once every 2 weeks. Patients requiring larger LDL-C reduction (>60%) may be started on 150 mg once every 2 weeks, or 300 mg once every 4 weeks (monthly), administered subcutaneously.²

PRALUENT: a PCSK9i that ticks all the boxes^1–4 PRALUENT is a PCSK9i that reduces the levels of LDL-C in the blood.² It is a fully human IgG1 monoclonal antibody that works by inhibiting the binding of PCSK9 to LDL- receptors. As a result, PRALUENT increases the number of LDL-receptors available to clear LDL, thereby lowering LDL-C levels.² Elevated LDL-C levels have been significantly associated with cardiovascular disease such as heart attacks and strokes.¹

AAD 2026 post-congress: Complete systemic therapy update. Multi-indication clinical data for inflammatory dermatological conditions.

AAD 2026 post-congress: Complete systemic therapy update. Multi-indication clinical data for inflammatory dermatological conditions.